ライフサイエンスコーパス: AVF

1 AVF blood flow rate at 1 day is usually more than 50% of

2 AVF draining vein diameter and blood flow rate were asse

3 AVF performance was significantly better along the horiz

4 AVF provides the appropriate parameter to account for pa

5 AVF success was defined as dialysis initiation using the

6 A total of 1084 accesses (185 AVF, 296 AVG, 603 CVC) were used for a total of 1381 per

7 native functional arterial properties affect AVF development.

8 Animals were sacrificed on day 7 after AVF placement for real-time polymerase chain reaction (n

9 d on the outflow vein at 7 and 21 days after AVF creation.

10 Eleven mice died after AVF placement.

11 ctively in 69 patients within 4 months after AVF placement; adequacy for dialysis was known in 54.

12 iameter at 1 day, 2 weeks, and 6 weeks after AVF placement.

13 When verified against AVF as the reference test, patients with a false-positiv

14 gative group when mfERG was verified against AVF suggests that mfERG may have the ability to detect c

15 t variable specificity when verified against AVF, OCT, FAF, and a combination of tests.

16 An AVF rather than the planned graft was placed in eight (1

17 eral jugular vein was connected to create an AVF, and CorMatrix scaffold was wrapped around the outfl

18 r (during 2004-2012) who subsequently had an AVF (n=295) or AVG (n=105) placed or no arteriovenous ac

19 g with an HC while awaiting maturation of an AVF (adjusted hazard ratio, 0.77; 95% CI, 0.76-0.79; P <

20 s study, our results suggest that placing an AVF >6-9 months predialysis in the elderly may not assoc

21 higher in patients who initially receive an AVF versus an AVG.

22 Patients receiving an AVF had a higher median annual cost (interquartile range

23 atients receiving an AVG, those receiving an AVF had more frequent surgical access procedures per yea

24 also approximately twice as likely to use an AVF (aOR 2.3; 95% CI 1.2 to 4.6).

25 tems are significantly more likely to use an AVF at initiation of HD than patients with other insuran

26 of a patient beginning hemodialysis using an AVF by 11-fold (odds ratio, 11.42 [95% CI, 10.93-11.93];

27 4.9% of subjects initiated dialysis using an AVF, and 45.1% of subjects used a catheter or graft.

28 40% were using an AVG, and 26% were using an AVF.

29 ere using an AVG, and 85 (14%) were using an AVF.

30 greater odds of initiating dialysis with an AVF (adjusted odds ratio [aOR] 10.3; 95% confidence inte

31 dently associated with initiating HD with an AVF (aOR 1.4; 95% CI 1.2 to 1.5).

32 anic patients initiated hemodialysis with an AVF less frequently despite being younger and having les

33 persistently initiated hemodialysis with an AVF less frequently than white patients (P < .05 for all

34 tients tend to initiate hemodialysis with an AVF less frequently than white patients despite being yo

35 uary 1, 2005, and December 31, 2008, with an AVF placed as the first predialysis access.

36 s in this cohort, first hemodialysis with an AVF ranged from 11.1% to 22.2% depending on the ESRD Net

37 hite patients initiated hemodialysis with an AVF than black patients or Hispanic patients (18.3% vs 1

38 e number of patients who initiate HD with an AVF.

39 ease, and cancer than white patients with an AVF.

40 rouped as follows: sham; sham+CIMP; AVF; and AVF+CIMP (n=6).

41 d histomorphometry of of the bone in cAF and AVF was significantly superior to bone grafts with a hig

42 ading to accelerated neointima formation and AVF failure.

43 increases in 6-week AVF blood flow rate and AVF diameter (per absolute 10% difference in FMD: change

44 with greater 6-week AVF blood flow rate and AVF diameter (per absolute 10% difference in NMD: change

45 s (180 women and 422 men, 459 with upper-arm AVF and 143 with forearm AVF) from seven clinical center

46 rvention prior to week 2, 70% with upper-arm AVFs (302 of 433) and 77% with forearm AVFs (99 of 128)

47 orearm AVFs (68 of 124) and 83% of upper-arm AVFs (341 of 411) in surviving patients without thrombos

48 9 of 459), and 87% (401 of 459) of upper-arm AVFs and in 40% (58 of 143), 73% (104 of 143), and 77% (

49 o be involved in the conversion of averufin (AVF) to versiconal hemiacetal acetate (VHA), in Aspergil

50 s needed to verify the linkages for baseline AVF as well as the response measures.

51 For baseline AVF, the best evidence was on 2q22.1 and 2q33.2-q36.3 (i

52 the elderly may not associate with a better AVF success rate.

53 initiation using the AVF, with time between AVF placement and dialysis start as our primary variable

54 ortion of positive test results, followed by AVF.

55 school performance in children with cerebral AVF and the American Spinal Injury Association impairmen

56 of gene mutations in pediatric cerebrospinal AVFs, and show the predominance of RASA1 over HHT mutati

57 ce were grouped as follows: sham; sham+CIMP; AVF; and AVF+CIMP (n=6).

58 estored the ability of the mutant to convert AVF to VHA and to produce aflatoxins B(1), G(1), B(2), a

59 Three groups were created: AVF (n = 6), conventional arterial flap (cAF, n = 6) and

60 After 7 and 21 days, AVFs or contralateral internal jugular veins were proces

61 compared these findings with those in failed AVFs from patients with ESRD.

62 Abdominal visceral fat (AVF), abdominal subcutaneous fat (ASF), and abdominal to

63 The loss of attentional visual field (AVF) has been linked to poor mobility and car crashes.

64 ce tomography (OCT), automated visual field (AVF), and angiograms.

65 The attentional visual field (AVF), which describes a person's ability to divide atten

66 when compared with automated visual fields (AVFs), fundus autofluorescence (FAF), and optical cohere

67 Arteriovenous fistula (AVF) access improves survival in patients with end-stage

68 ed with the use of an arteriovenous fistula (AVF) at first hemodialysis.

69 d the outflow vein of arteriovenous fistula (AVF) at the time of creation could reduce VNH.

70 irst occurrence of an arteriovenous fistula (AVF) in a transplanted allograft bundle (3).

71 dialysis (HD) with an arteriovenous fistula (AVF) in countries with universal health care systems com

72 Arteriovenous fistula (AVF) is the preferred type of vascular access for hemodi

73 Arteriovenous fistula (AVF) is the preferred vascular access for hemodialysis (

74 Arteriovenous fistula (AVF) maturation failure is the primary cause of dialysis

75 f death, high rate of arteriovenous fistula (AVF) maturation failure, and poor vascular access outcom

76 Low rates of arteriovenous fistula (AVF) maturation prevent optimal fistula use for hemodial

77 hemodialysis (HD) via arteriovenous fistula (AVF) or arteriovenous graft (AVG) vs hemodialysis cathet

78 go placement of a new arteriovenous fistula (AVF) or arteriovenous graft (AVG).

79 ncident and prevalent arteriovenous fistula (AVF) use among patients with ESRD.

80 Arteriovenous fistula (AVF) was created in C57BL/J6 mice, and CIMP was administ

81 through an autologous arteriovenous fistula (AVF), 49% through a prosthetic graft (AVG), and 23% thro

82 rebral or spinal pial arteriovenous fistula (AVF), and to describe their clinical characteristics.

83 Arteriovenous fistulae (AVF) have advantages over arteriovenous grafts (AVG) and

84 1 year were 16% for arteriovenous fistulas (AVFs) and 23% for polytetrafluoroethylene (PTFE) grafts.

85 he failure of 60% of arteriovenous fistulas (AVFs) within 2 years.

86 In arterialized venous flaps (AVFs) the venous network is used to revascularize the fl

87 Annual mortality rates were 11.7% for AVF, 14.2% for AVG, and 16.1% for CVC.

88 After adjusting for AVF area, we found that poorer cognitive and vision perf

89 After controlling for AVF location, preoperative ultrasound measurements, and

90 To assess the optimal time for AVF placement in the elderly, we linked data from the US

91 ar primary assisted patency rates of 67% for AVFs and 68% for PTFE grafts.

92 -9 months predialysis compared with 0.72 for AVFs created >12 months predialysis (P<0.001).

93 , with a mean of 0.64 procedures/patient for AVFs created 6-9 months predialysis compared with 0.72 f

94 459 with upper-arm AVF and 143 with forearm AVF) from seven clinical centers underwent preoperative

95 In 55% of forearm AVFs (68 of 124) and 83% of upper-arm AVFs (341 of 411)

96 104 of 143), and 77% (110 of 143) of forearm AVFs at 1 day, 2 weeks, and 6 weeks, respectively.

97 r-arm AVFs (302 of 433) and 77% with forearm AVFs (99 of 128) maintained at least 85% of their week 2

98 t fraction (i.e., adipocyte volume fraction [AVF]) and not chemical fat fraction, because fat fractio

99 increase in MMP activity in the hearts from AVF mice compared with sham, and treatment with CIMP dec

100 The success rate increased as time from AVF creation to HD initiation increased from 1-3 months

101 tients initiated dialysis with a functioning AVF or AVG; 46.8% of AVFs were created <90 days before d

102 idelines in 1997 recommending 50% or greater AVF rates in incident HD patients.

103 ia (VNH) at the outflow vein of hemodialysis AVF is a major factor contributing to failure.

104 ntional procedures performed on hemodialysis AVFs and AVGs is relatively low.

105 To identify how AVFs fail, we anastomosed the carotid artery to the inte

106 In human AVF and a mouse aortocaval fistula model, Eph-B4 protein

107 milarly, ETS-1 expression increased in human AVFs compared with normal veins.

108 identity; increased Eph-B activity improves AVF patency.

109 In AVF mice, the cardiac pressure-length relationship was s

110 e calculated the 30-month slope of change in AVF prevalence from monthly facility reports collected b

111 The overall change in AVF was -0.34 degrees (SD = 4.32), which was a significa

112 eased plasma and LV tissue levels of CIMP in AVF mice; there was no increase in sham animals.

113 e risk factors associated with a decrease in AVF over time among participants in the Salisbury Eye Ev

114 were increased in AVF mice and decreased in AVF mice treated with CIMP.

115 Compared with sham, CIMP was decreased in AVF mice, and CIMP protein transfer increased plasma and

116 the standard deviation for the difference in AVF over 2 years of 4.3 degrees , two subgroups were cre

117 TS-1 as a mediator of neointima formation in AVF and may result in the development of novel strategie

118 ESRD but not with subsequent improvement in AVF use among prevalent patients.

119 arker of oxidative stress, were increased in AVF mice and decreased in AVF mice treated with CIMP.

120 Akt1 expression also increased in AVF; Akt1 knockout mice showed reduced fistula diameter

121 Loss in AVF over time is related independently to decrements in

122 le of ETS-1 in the formation of neointima in AVF.

123 In AVFs, ETS-1 mRNA increased 2.5-fold at 7 days and 4-fold

124 to bone grafts with a higher bone volume in AVFs (p = 0.01).

125 k Programs in the United States and incident AVF frequency.

126 ounty-level poverty and ascertained incident AVF use from the Medicare CMS 2728 form.

127 to compare patient characteristics, incident AVF frequencies, and corrected mortality hazards between

128 Current incident AVF practice falls exceedingly short years after recomme

129 ula First Catheter Last) target for incident AVF access.

130 ed regional variation in functional incident AVF frequency and risk-adjusted ESRD mortality exists ac

131 y poverty inversely associated with incident AVF use (P for trend = 0.001).

132 reatment is located associates with incident AVF use by patients with ESRD but not with subsequent im

133 s of temporary catheters and the overall low AVF maturation rate explain why a universal policy of AV

134 However, many AVFs fail before starting dialysis.

135 Mean AVF diameters of at least 0.40 cm were seen in 85% (389

136 embryonic venous determinant Eph-B4 mediates AVF maturation.

137 tcome Measure: Epidemiologic, clinical, OCT, AVF, angiographic, and electrophysiological data at base

138 proach taking into account the likelihood of AVF maturation.

139 US measurements of AVF at 2-4 months in patients undergoing hemodialysis ar

140 eoperative VFT to ultrasound measurements of AVF blood flow rate and venous diameter at 1 day, 2 week

141 he population, 14% lost 5 degrees or more of AVF.

142 Utilization rates of AVF, arteriovenous graft, and intravascular hemodialysis

143 dventitia of the outflow vein at the time of AVF creation in the MSC group.

144 ent of novel strategies for the treatment of AVF dysfunction.

145 Treatment of AVF mice with CIMP significantly abrogated the contracti

146 ysis with a functioning AVF or AVG; 46.8% of AVFs were created <90 days before dialysis initiation.

147 mia, activates Notch in endothelial cells of AVFs, leading to accelerated neointima formation and AVF

148 The concept of AVFs in osseous flaps may be feasible for revascularizat

149 ch intracellular domain compared with ECs of AVFs in pair-fed control mice.

150 , and Notch target genes increased in ECs of AVFs in uremic mice.

151 Endothelial cells (ECs) of AVFs in uremic mice or patients expressed mesenchymal ma

152 While the feasibility of AVFs in soft tissues has been reported there is no study

153 ical management, with an increased number of AVFs placed and an improved likelihood of selecting the

154 ifferences in the patterns of utilization of AVFs are unknown and deserve evaluation.

155 ESRD program may mitigate poverty effects on AVF use.

156 in surviving patients without thrombosis or AVF intervention prior to 6 weeks, at least 50% of their

157 ong surviving patients without thrombosis or AVF intervention prior to week 2, 70% with upper-arm AVF

158 e aim to assess the flap survival of osseous AVFs in a pig model.

159 s been reported there is no study on osseous AVFs.

160 Overall AVF extent was predicted by vision and cognitive measure

161 ts with at least one cerebral or spinal pial AVF were screened for genetic disease.

162 ficant relationships with both postoperative AVF blood flow rate and diameter.

163 functional properties predict postoperative AVF measurements, patients enrolled in the Hemodialysis

164 ore common in patients receiving predialysis AVF than in patients receiving AVG (46.0% versus 28.5%;

165 /= 70 years) with CKD undergoing predialysis AVF or arteriovenous graft (AVG) creation from 2004 to 2

166 In all, 67% of patients with predialysis AVF and 71% of patients with predialysis AVG creation in

167 contrast, substantial increases in prevalent AVF rates from 30.9 to 38.6% (P < 0.001) among treatment

168 -abdominal infections, and, al. though rare, AVF.

169 ilure, almost one half of patients receiving AVFs initiated dialysis with a catheter.

170 remodeling suggesting that Eph-B4 regulates AVF venous adaptation through an Akt1-mediated mechanism

171 Symmetrically shaped AVFs were found in just 34% of participants.

172 ic artery-superior mesenteric vein (SMA-SMV) AVF in a pancreas-after-kidney (PAK) transplant recipien

173 ion impairment scale in children with spinal AVF.

174 to a universal health care model, we studied AVF use within these organizations.

175 ving an asymmetric as opposed to a symmetric AVF shape profile.

176 performance was associated with a symmetric AVF shape.

177 These results show that AVF maturation is associated with acquisition of dual ar

178 These same authors promoted the theory that AVF formation was directly related to procurement techni

179 The AVF group had a higher median overall annual access-rela

180 The AVF placement rate increased from 32% (126 of 395 patien

181 The AVF was assessed using a divided-attention protocol with

182 purposes of this study were to describe the AVF in a large sample of older drivers and identify demo

183 llowed by a synthetic vascular access if the AVF did not mature compared to (2) placing a synthetic v

184 very little is known about the shape of the AVF and the factors that affect it.

185 The shape of the AVF was classified as either symmetric or one of two asy

186 he legs, and the hand and leg closest to the AVF or AVG received a higher dose.

187 was defined as dialysis initiation using the AVF, with time between AVF placement and dialysis start

188 AVF1st was the dominant strategy when the AVF maturation rate was 69% or greater.

189 The AVFs were created by anastomosis of genicular artery wit

190 C57BL/J6 mice, and CIMP was administered to AVF and sham mice by protein transfer into peritoneal ca

191 nd this measure is shown to be equivalent to AVF.

192 VA and 11 VB ventral cord motor neurons, two AVF interneurons and in unidentified neurons of the retr

193 study, 82.6% initiated HD via HC, 14.0% via AVF, and 3.4% via AVG.

194 One-day and 2-week AVF flow rates and diameters were used to predict 6-week

195 , greater NMD associated with greater 6-week AVF blood flow rate and AVF diameter (per absolute 10% d

196 associated with greater increases in 6-week AVF blood flow rate and AVF diameter (per absolute 10% d

197 positively associated with changes in 6-week AVF blood flow rate and diameter, suggesting that native

198 central venous catheters (CVC), but whether AVF are associated independently with better survival is

199 ognitive, and vision factors associated with AVF performance and shape.

200 Symptoms associated with AVF were recorded: heart failure, neurological deficit/s

201 relative hazards (RH) of death compared with AVF were 1.5 (95% confidence interval, 1.0 to 2.2) for C

202 azards associated with CVC, as compared with AVF, were stronger in men (n = 334; RH = 2.0; P = 0.01)

203 Those initiating HD with AVF had 23% lower mortality than those initiating with a

204 Patients initiating HD with AVF had 35% lower mortality than those with HC (adjusted

205 and 52% (CI, 0.29-0.74), respectively, with AVF as reference standard (13 studies).